ADVERTISEMENT

Hympavzi (marstacimab): New Treatment for Hemophilia

On 11 October 2024, Hympavzi (marstacimab-hncq), a human monoclonal antibody targeting “tissue factor pathway inhibitor” received US FDA’s approval as a new drug for prevention of bleeding episodes in individuals with hemophilia A or hemophilia B.  

Earlier, on 19 September 2024, Hympavzi was granted marketing authorisation by European Medicine Agency (EMA) for prophylaxis of bleeding episodes in patients with severe hemophilia A or B. 

Hemophilia A is an inherited bleeding disorder caused by a lack of blood clotting factor VIII while hemophilia B is caused by insufficiency of the clotting factor IX. Both the conditions are conventionally treated by replacing missing blood clotting factors by injections.  

Hympavzi prevents bleeding episodes by a different process. It targets the naturally occurring anticoagulation protein called “tissue factor pathway inhibitor” and reduces its anticoagulation activity thereby increasing the amount of thrombin.  

The new drug provides a new treatment option to the patients. This is first, non-factor and once-weekly treatment for hemophilia B. 

FDA’s approval of Hympavzi is based on satisfactory results from the phase 3 multicentre clinical trial that evaluated its safety and efficacy in adolescent and adult participants ages 12 to <75 years with severe hemophilia A or moderately severe to severe hemophilia B.  

*** 

Sources:  

  1. FDA News release – FDA Approves New Treatment for Hemophilia A or B. Posted on 11 October 2024. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-hemophilia-or-b  
  1. EMA. Hympavzi – Marstacimab. Available at https://www.ema.europa.eu/en/medicines/human/EPAR/hympavzi  

*** 

SCIEU Team
SCIEU Teamhttps://www.ScientificEuropean.co.uk
Scientific European® | SCIEU.com | Significant advances in science. Impact on humankind. Inspiring minds.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Most Popular Articles

First Detection of Secondary Atmosphere around an Exoplanet  

A study involving measurements by James Webb Space Telescope...

COVID-19: Severe lung infection affects heart through “cardiac macrophage shift” 

It is known that COVID-19 increases the risk of...

Anthrobots: The First Biological Robots (Biobots) Made from Human Cells

The word ‘robot’ evokes images of human-like manmade metallic...
- Advertisement -
93,458FansLike
47,393FollowersFollow
1,772FollowersFollow
30SubscribersSubscribe